Search - tctmd.com

Displaying 1 - 20 of 106

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Data Deliverance: Updated PFO Closure for Cryptogenic Stroke Clinical Trial Review and Guidelines

Presenter: John D. Carroll, Brij Maini, Lars Sondergaard

June 23, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #3: Novel Tips and Tricks to Simplify TAVI

Presenter: Fabian Nietlispach

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #2: Economic Benefits With a Minimalist TAVR Strategy Are Indisputable!

Presenter: Hemal Gada

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Snapshot #1: Preserving TEE is Fundamental Results From a High-Volume Minimalist TAVR Center

Presenter: Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Voice of Interventional Echocardiography: Situations where TEE Provides Meaningful Value During TAVR (With Convincing Case Examples)

Presenter: Vinod H. Thourani, John G. Webb, Rebecca T. Hahn

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Vancouver Minimalist Clinical Care Pathway: Updates from the 3M Trial and Evolution to BENCHMARK

Presenter: Vinod H. Thourani, John G. Webb, David A. Wood

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Self-Expanding Single-Operator CENTERA TAVR System: Clinical Data and Plans for the US Pivotal Trial

Presenter: Martin B. Leon

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Minimalist TAVR Strategy Should be the Default Approach Supported by Clinical Outcomes and Economic Benefits

Presenter: Vinod H. Thourani, John G. Webb

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Raj Makkar

June 22, 2018

Program Update: The ACCURATE NEO TAVR System - Design Characteristics, Clinical Data, and Future Vision

Presentation The Structural Heart Disease Summit 2018

Program Update: The ACURATE NEO TAVR System - Design Characteristics, Clinical Data, and Future Vision

Presenter: Axel Linke, Vinod H. Thourani, Alexandre Abizaid

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Raj Makkar, Maria Alu, MS

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Raj Makkar, Lars Sondergaard

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Program Update: The PORTICO TAVR System - Design Characteristics, Clinical Data, and Future Vision

Presenter: Axel Linke, Vinod H. Thourani, Raj Makkar

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Presenter: Patrick Klein

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

Presenter: Howard C. Herrmann, Allan Schwartz, Eberhard Grube

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A)

Presenter: Francesco Maisano

June 22, 2018

Program Update: The LOTUS TAVR System: Design Characteristics, Clinical Data, and Future Vision

Presentation The Structural Heart Disease Summit 2018

Program Update: The LOTUS Edge TAVR System: Design Characteristics, Clinical Data, and Future Vision

Presenter: Axel Linke, Vinod H. Thourani, Ted Feldman

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Presenter: Howard C. Herrmann, Allan Schwartz, Jonathan Afilalo

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

Presenter: Howard C. Herrmann, Allan Schwartz, Suzanne V. Arnold

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device: The SAFE MANTA Study

Presenter: David A. Wood

June 22, 2018

Advertisement

Data Deliverance: Updated PFO Closure for Cryptogenic Stroke Clinical Trial Review and Guidelines

Snapshot #3: Novel Tips and Tricks to Simplify TAVI

Snapshot #2: Economic Benefits With a Minimalist TAVR Strategy Are Indisputable!

Snapshot #1: Preserving TEE is Fundamental Results From a High-Volume Minimalist TAVR Center

The Voice of Interventional Echocardiography: Situations where TEE Provides Meaningful Value During TAVR (With Convincing Case Examples)

The Vancouver Minimalist Clinical Care Pathway: Updates from the 3M Trial and Evolution to BENCHMARK

The Self-Expanding Single-Operator CENTERA TAVR System: Clinical Data and Plans for the US Pivotal Trial

The Minimalist TAVR Strategy Should be the Default Approach Supported by Clinical Outcomes and Economic Benefits

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Program Update: The ACURATE NEO TAVR System - Design Characteristics, Clinical Data, and Future Vision

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Program Update: The PORTICO TAVR System - Design Characteristics, Clinical Data, and Future Vision

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A)

Program Update: The LOTUS Edge TAVR System: Design Characteristics, Clinical Data, and Future Vision

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device: The SAFE MANTA Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content